Hemosiderosis classification: Difference between revisions
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Based on the duration of symptoms, [[PH]] may be classified as an either acute or chronic phase.[[PH]] may be classified into three groups based on disease characteristic: first group with circulating anti-glomerular basement membrane (anti-GBM) antibodies, second group, with immune complex disease, and the third group without known immunologic association or (IPH). | |||
==Classification== | ==Classification== | ||
Revision as of 05:39, 28 September 2020
|
Hemosiderosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemosiderosis classification On the Web |
|
American Roentgen Ray Society Images of Hemosiderosis classification |
|
Risk calculators and risk factors for Hemosiderosis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Based on the duration of symptoms, PH may be classified as an either acute or chronic phase.PH may be classified into three groups based on disease characteristic: first group with circulating anti-glomerular basement membrane (anti-GBM) antibodies, second group, with immune complex disease, and the third group without known immunologic association or (IPH).
Classification
Based on the duration of symptoms, IPH may be classified as either acute or chronic phase.
- In acute phase, patients presents with sudden onset of severe dyspnea and hemoptysis, which, if not treated immediately, could be fatal.
- In chronic phase, some children may present with weight loss and failure to thrive or hypoxemic respiratory failure.
IPH may be classified into three groups based on disease characteristic:
- Group 1 pulmonary hemosiderosis involves PH with circulating anti-GMB antibodies which affecting the capillary system.
- Group 2 pulmonary hemosiderosis involves PH with an immune complex disease such as systemic lupus erythematosus, SLE.
- Group 3 pulmonary hemosiderosis involves no demonstrable immune system involvement.